Replimune Group, Inc. (REPL)
Data as of , from SEC Form 4 filings.
See up to 3 months of REPL. The 7-day demo opens the 1M and 3M ranges and puts REPL on your watchlist.
Start 7-day demoLatest REPL insider trades
About Replimune Group, Inc. (REPL)
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
- WOBURN, MA
- 465
- 2018
- XNAS
REPL Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 2 | 2,736,340 | $33.00M |
| Open-market sale | 5 | 79,124 | $1.04M |
| Bona-fide gift | 1 | 50,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
REPL insider transactions (Form 4)
3838 Form 4 filings on record, the earliest from Nov 20, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Philip Astley-Sparke - Director | Gift | Common Stock | 50,000 | $0.00 | - | |
| Emily Luisa Hill - Officer | Open-market sale | Common Stock | 9,256 footnote F1 | $14.28 footnote F2 | $132K | |
| ||||||
| Sushil Patel - Officer | Open-market sale | Common Stock | 39,341 footnote F1 | $12.97 | $510K | |
| ||||||
| Emily Luisa Hill - Officer | Open-market sale | Common Stock | 11,448 footnote F1 | $12.97 | $148K | |
| ||||||
| Konstantinos Xynos - Officer | Open-market sale | Common Stock | 11,447 footnote F1 | $12.97 | $148K | |
| ||||||
 Andrew Schwendenman - Officer | Open-market sale | Common Stock | 7,632 footnote F1 | $12.97 | $99K | |
| ||||||
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | 2026 $0.0001 Prefunded Warrants | 126,394 footnote F1 | $12.06 | $1.52M | |
| BAKER BROS. ADVISORS LP - Director | Open-market purchase | 2026 $0.0001 Prefunded Warrants | 2,609,946 footnote F1 | $12.06 | $31.48M | |
| ||||||
| Christopher Sarchi - Officer | Open-market sale | Common Stock | 12,000 footnote F1 | $9.24 footnote F2 | $111K | |
| ||||||
| Konstantinos Xynos - Officer | Open-market sale | Common Stock | 14,023 footnote F1 | $5.08 footnote F2 | $71K | |
| ||||||
| Andrew Schwendenman - Officer | Open-market sale | Common Stock | 7,894 footnote F1 | $5.08 footnote F2 | $40K | |
| ||||||
| Christopher Sarchi - Officer | Open-market sale | Common Stock | 8,626 footnote F1 | $5.08 footnote F2 | $44K | |
| ||||||
| Philip Astley-Sparke - Director | Open-market sale | Common Stock | 17,657 footnote F1 | $5.08 footnote F2 | $90K | |
| ||||||
| Sushil Patel - Officer | Open-market sale | Common Stock | 37,324 footnote F1 | $5.08 footnote F2 | $190K | |
| ||||||
| Emily Luisa Hill - Officer | Open-market sale | Common Stock | 7,812 footnote F1 | $5.08 footnote F2 | $40K | |
| ||||||
| BAKER BROS. ADVISORS LP | Grant or award | Non-Qualified Stock Option (right to buy)uy) | 44,500 footnote F1 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Non-Qualified Stock Option (right to buy)uy) | 44,500 footnote F1 | $0.00 | - | |
| ||||||
| Christopher Sarchi - Officer | Grant or award | Common Stock | 50,000 footnote F1 | $0.00 | - | |
| Christopher Sarchi - Officer | Grant or award | Employee Stock Option (right to buy) | 75,000 | $0.00 | - | |
| ||||||
| Philip Astley-Sparke - Director | Grant or award | Common Stock | 50,000 footnote F1 | $0.00 | - | |
| Philip Astley-Sparke - Director | Grant or award | Stock Option (right to buy) | 75,000 | $0.00 | - | |
| ||||||
| Christy J. Oliger - Director | Grant or award | Stock Option (right to buy) | 44,500 | $0.00 | - | |
| Konstantinos Xynos - Officer | Grant or award | Common Stock | 50,000 footnote F1 | $0.00 | - | |
| Konstantinos Xynos - Officer | Grant or award | Employee Stock Option (right to buy) | 75,000 | $0.00 | - | |
| ||||||
| Madhavan Balachandran - Director | Grant or award | Stock Option (right to buy) | 44,500 | $0.00 | - | |
| Andrew Schwendenman - Officer | Grant or award | Common Stock | 36,667 footnote F1 | $0.00 | - | |
| Andrew Schwendenman - Officer | Grant or award | Employee Stock Option (right to buy) | 55,000 | $0.00 | - | |
| ||||||
| Sushil Patel - Officer | Grant or award | Common Stock | 251,240 footnote F1 | $0.00 | - | |
| Sushil Patel - Officer | Grant or award | Employee Stock Option (right to buy) | 376,860 | $0.00 | - | |
| ||||||
 Kapil Dhingra - Director | Grant or award | Stock Option (right to buy) | 44,500 | $0.00 | - | |
| Paolo Pucci - Director | Grant or award | Stock Option (right to buy) | 44,500 | $0.00 | - | |
| Joseph P. Slattery - Director | Grant or award | Stock Option (right to buy) | 44,500 | $0.00 | - | |
 Veleka Peeples-Dyer - Director | Grant or award | Stock Option (right to buy) | 44,500 | $0.00 | - | |
| Emily Luisa Hill - Officer | Grant or award | Common Stock | 50,000 footnote F1 | $0.00 | - | |
| Emily Luisa Hill - Officer | Grant or award | Employee Stock Option (right to buy) | 75,000 | $0.00 | - | |
| ||||||
| Dieter Weinand - Director | Grant or award | Stock Option (right to buy) | 44,500 | $0.00 | - | |
| Christopher Sarchi - Officer | Open-market sale | Common Stock | 6,500 | $8.01 footnote F2 | $52K | |
| ||||||
| Philip Astley-Sparke - Director | Gift | Common Stock | 25,000 | $0.00 | - | |
Item 5.03, 5.07, 9.01
Item 2.02, 9.01
Item 8.01, 9.01
Item 8.01, 9.01
REPL insider trading FAQ
What is the latest insider trade for REPL?
Replimune Group, Inc. (REPL) had 7 insider filings in the last 90 days, with the most recent on 2026-08-24. The full record for REPL runs to 38 Form 4 filings, the earliest from 2024-11-20. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying REPL stock?
2 insider purchases of REPL were filed in the last 90 days, totaling $33.00M.
How many insiders are selling REPL stock?
5 insider sales of REPL were filed in the last 90 days, totaling $1.04M.
Where can I see REPL SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects REPL Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Philip Astley-Sparke view on EDGAR
- - Emily Luisa Hill view on EDGAR
- - Sushil Patel view on EDGAR
- - Emily Luisa Hill view on EDGAR
- - Konstantinos Xynos view on EDGAR
- - Andrew Schwendenman view on EDGAR
- - BAKER BROS. ADVISORS LP view on EDGAR
- - Christopher Sarchi view on EDGAR
- - Konstantinos Xynos view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where REPL's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow REPL with a 7-day demo
- REPL on your watchlist
- Every REPL Form 4 filing on record
- Up to 3 months of REPL price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
